A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
Fatima H. Karzai
No relevant relationships to disclose
Avani Atul Shah
No relevant relationships to disclose
Michelle A. Ojemuyiwa
No relevant relationships to disclose
Ravi Amrit Madan
No relevant relationships to disclose
Andrea Borghese Apolo
No relevant relationships to disclose
Nancy Ann Dawson
No relevant relationships to disclose
Philip M. Arlen
No relevant relationships to disclose
Marc Robert Theoret
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
Clara Chen
No relevant relationships to disclose
Jane B. Trepel
No relevant relationships to disclose
Anna Couvillon
No relevant relationships to disclose
Guinevere Chun
No relevant relationships to disclose
Nancy Harold
No relevant relationships to disclose
Seth M. Steinberg
No relevant relationships to disclose
Douglas K. Price
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose
William Douglas Figg
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose